iconstar paper   HIV Articles  
Back grey arrow rt.gif
 
 
Activation and Senescence Markers in HIV Patients with Chronic Kidney Disease
 
 
  CROI 2016
Reported by Jules Levin
 
The proportion of all comorbidities was higher among patients with an eGFR <60 (p<0.01), except
for hypertension and degenerative CNS disorders. Patients with an eGFR <60 were also more likely to present two or more comorbidities (57% vs. 29%, p<0.01).
 
• an increase of the CIADIS score was
significantly associated with an eGFR<60, (OR=1.2; 95% CI
1.0-1.5; P=0.04)(Figure 2,3 and 4) and eGFR <90 (OR=1.1;
95% CI 1.0-1.2; P<0.01) (Data not shown).
 
• The CIADIS score remained significantly associated with an
eGFR <60 after adjustement for the number of comorbidities
(OR=1.2; 95% CI 1.0-1.5; P=0.04) (Figure 2), diabetes

(OR=1.5; 95% CI 1.0-2.2; P=0.04) (Figure 3) or for
cardiovascular events (OR=1.5; 95% CI 1.0-2.3; P=0.04)
(Figure 4) but not for the other comorbidities.
 
The CIADIS score was determined with CD4 and CD8 activation (DR+), maturation (T naive, memory) and senescence (CD57+CD28-) markers (Duffau et al. AIDS in press)

0617191

0617192

program abstract
 
ART-treated HIV-infected individuals remain at higher risk for chronic kidney disease (CKD) than the general population and multiple causes are hypothesized. We evaluated the association between T cell immune activation (IA) and -senescence (IS), and CKD in these patients.
 
Patients with undetectable viral load and an estimated Glomerular Filtration Rate (eGFR) measurement were part of the cross-sectional CIADIS substudy (2011-2013) of the ANRS CO3 Aquitaine cohort. The CIADIS score was determined with CD4 and CD8 activation (DR+), maturation (T naive, memory) and senescence (CD57+CD28-) markers (Duffau et al. AIDS in press): positive values represent a phenotype with high IA and IS, negative values a profile with low IA/IS and with high proportion of naive T cells. The association between the CIADIS score and CKD was evaluated for two separate outcomes: i) eGFR <60 mL/min/1.73m2 and ii) eGFR<90 mL/min/1.73m2. Logistic regression models adjusted for age, sex, tenofovir (TDF) use and non-HIV related comorbidities (diabetes, cardiovascular events, dyslipidemias, hypertension and cancer) were constructed. In a sub-group analysis, urine protein-creatinine ratio (uPCr) >30 mg/mmol was combined with eGFR≥90 to define early kidney dysfunction.
 
We included 849 patients with a median age of 51 years; 74% were men, 23% at CDC stage C; they were on ART for a median of 13 years, 85% of patients had an ongoing or previous TDF-containing regimen. eGFR was ≥90, 60-89 and <60 in 68 %, 28% and 4% of patients, respectively. The median CIADIS score was -0.1 (IQR -1.5;1.5) and increased significantly with decreasing kidney function (Figure). In univariable analysis: an increase of the CIADIS score was significantly associated with an eGFR<60, (OR=1.2; 95% CI 1.0-1.5; P=0.04) and eGFR<90 (OR=1.1; 95% CI 1.0-1.2; P<0.01). After adjustment, the CIADIS score remained significantly associated with an eGFR<60 (OR=1.3; 95% CI 1.0-1.6; P=0.03) only. Among 221 patients with an eGFR ≥90 and available uPCr, 9% had an early kidney dysfunction. No difference in the score was found whether uPCr was ≤30 or >30 (P=0.46). Higher IA and IS levels were independently associated with advanced CKD. Although other factors may contribute to kidney damage, persisting T-cells activation and senescence could induce inflammation and thus play a direct role even in successfully treated patients. Follow-up continues; longitudinal analysis will allow studying the development of CKD according to IA/IS profiles.

0617193

0617194

0617195

0617196

0617197

References:
1. Winston JA. et al. HIV and CKD epidemiology. Adv Chronic Kidney Dis. 2010 Jan;17(1):19-25
2. Lucas GM. et al. End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS. 2007 Nov;21(18):2435-43
3, Longenecker et al. Rosuvastatin Preserves Renal Function and Lowers Cystatin C in HIV-Infected Subjects on Antiretroviral Therapy: The SATURN-HIV Trial. Clin. Inf. Dis. 2014. Oct;59(8):1148-56
4. Duffau P. , Wittkop L. et al. Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients. AIDS. 2015 Oct;29(16):2099-108

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org